We are live on ! Find out more
PHP

Parkman Healthcare Partners Portfolio holdings

AUM $970M
1-Year Est. Return 79.46%
This Fund
S&P 500
This Quarter Est. Return
+37.02%
1 Year Est. Return
+79.46%
3 Year Est. Return
+312.89%
5 Year Est. Return
+648.59%
10 Year Est. Return
–
AUM
$390M
AUM Growth
+$12.6M
Cap. Flow
-$64M
Cap. Flow %
-16.4%
Top 10 Hldgs %
30.29%
Holding
100
New
16
Increased
29
Reduced
38
Closed
17

Top Buys

Rank Stock Value
1
SDGR icon
Schrodinger
SDGR
+$6.67M
2
ARWR icon
Arrowhead Research
ARWR
+$4.3M
3
DXCM icon
DexCom
DXCM
+$4.27M
4
AVTR icon
Avantor
AVTR
+$3.89M
5
IONS icon
Ionis Pharmaceuticals
IONS
+$3.76M

Top Sells

Rank Stock Value
1
NBIX icon
Neurocrine Biosciences
NBIX
+$12.7M
2
MRK icon
Merck
MRK
+$10.4M
3
AXNX
Axonics, Inc. Common Stock
AXNX
+$9.03M
4
MASI
Masimo
MASI
+$8.26M
5
VRTX icon
Vertex Pharmaceuticals
VRTX
+$6.12M

Sector Composition

Rank Sector Weight
1 Healthcare 92.05%
2 Technology 1.31%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
SNDX icon
76
Syndax Pharmaceuticals
SNDX
$1.77B
$698K 0.18%
31,386
+1,381
+5% +$28.6K
FATE icon
77
Fate Therapeutics
FATE
$317M
$692K 0.18%
+7,615
New +$473K
FOCL
78
EDAP TMS S.A.
FOCL
$178M
$672K 0.17%
129,889
+4,889
+4% +$22K
CNCE
79
DELISTED
Concert Pharmaceuticals, Inc.
CNCE
$636K 0.16%
+50,290
New +$573K
VSTM icon
80
Verastem
VSTM
$629M
$536K 0.14%
+20,954
New +$421K
RAPT
81
DELISTED
RAPT Therapeutics
RAPT
$497K 0.13%
3,147
-604
-16% -$131K
PHAS
82
DELISTED
PhaseBio Pharmaceuticals, Inc. Common Stock
PHAS
$371K 0.1%
+110,547
New +$396K
WHWK
83
Whitehawk Therapeutics
WHWK
$269M
$259K 0.07%
17,625
-2,375
-12% -$50.8K
AMRN
84
Amarin Corp
AMRN
$297M
– –
-5,808
Closed -$489K
APRE icon
85
Aprea Therapeutics
APRE
$8.46M
– –
-1,002
Closed -$482K
ATXS
86
DELISTED
Astria Therapeutics
ATXS
– –
-24,250
Closed -$901K
DVAX
87
DELISTED
Dynavax Technologies
DVAX
– –
-200,000
Closed -$864K
GDRX icon
88
GoodRx Holdings
GDRX
$1.22B
– –
-10,000
Closed -$556K
MASI
89
DELISTED
Masimo
MASI
– –
-35,000
Closed -$8.26M
MGTX icon
90
MeiraGTx Holdings
MGTX
$1.2B
– –
-130,763
Closed -$1.73M
MNKD icon
91
MannKind Corp
MNKD
$1.24B
– –
-351,230
Closed -$660K
MRK icon
92
Merck
MRK
$328B
– –
-131,874
Closed -$10.4M
NBIX icon
93
Neurocrine Biosciences
NBIX
$15.9B
– –
-132,544
Closed -$12.7M
QDEL icon
94
QuidelOrtho
QDEL
$1.02B
– –
-5,001
Closed -$1.1M
VRTX icon
95
Vertex Pharmaceuticals
VRTX
$133B
– –
-22,501
Closed -$6.12M
ZYME icon
96
Zymeworks
ZYME
$1.77B
– –
-85,000
Closed -$3.96M
AXNX
97
DELISTED
Axonics, Inc. Common Stock
AXNX
– –
-176,950
Closed -$9.03M
INOV
98
DELISTED
Inovalon Holdings, Inc. Class A Common Stock
INOV
– –
-50,000
Closed -$1.32M
MSON
99
DELISTED
Misonix Inc
MSON
– –
-135,596
Closed -$1.59M
ALXN
100
DELISTED
Alexion Pharmaceuticals
ALXN
– –
-50,000
Closed -$5.72M
1 2 3
4

Similar funds

LOIM
Liberty One Investment Management Libertyville, Illinois $970M AUM 12.15% 1-Year Est. Return
MGCM
Mane Global Capital Management New York $971M AUM 58.5% 1-Year Est. Return
JWM
Jackson Wealth Management Lake Mary, Florida $972M AUM 22.58% 1-Year Est. Return
WAM
WNY Asset Management Williamsville, New York $967M AUM
GHC
Graham Holdings Company Arlington, Virginia $967M AUM 15.12% 1-Year Est. Return
SAM
Stansberry Asset Management Westlake, Texas $973M AUM 21.39% 1-Year Est. Return
TCCM
Two Creeks Capital Management New York $974M AUM 2.54% 1-Year Est. Return
UIC
Uniplan Investment Counsel Milwaukee, Wisconsin $974M AUM 21.37% 1-Year Est. Return

Parkman Healthcare Partners's Q4 2020 Portfolio in Review

As of Q4 2020, Parkman Healthcare Partners held 100 positions worth $390M, up 3.3% from $378M the previous quarter. Its ten largest holdings account for 30% of the portfolio.

Parkman Healthcare Partners withdrew a net $64M in Q4 2020, closing 17 positions and reducing 38 holdings. Its most notable exit was Neurocrine Biosciences, an estimated $12.7M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 92% of assets, down from 92% a quarter earlier, followed by Technology.

Against the trend, Parkman Healthcare Partners opened a new position in Avantor worth $4.25M.

  • Parkman Healthcare Partners's largest Q4 2020 buy was Avantor: 150,872 shares worth $4.25M.
  • Parkman Healthcare Partners added most to Schrodinger in Q4 2020, an estimated $6.67M increase.
  • Parkman Healthcare Partners's biggest Q4 2020 reduction was Edwards Lifesciences, cutting an estimated $5.97M.
  • Parkman Healthcare Partners fully exited Neurocrine Biosciences in Q4 2020, selling an estimated $12.7M.
  • Parkman Healthcare Partners's ten largest holdings make up 30% of its $390M portfolio in Q4 2020.
  • Parkman Healthcare Partners opened 16 new positions and closed 17 in Q4 2020.
  • Parkman Healthcare Partners's portfolio value rose 3.3% quarter-over-quarter to $390M.

Based on Parkman Healthcare Partners's 13F filing for Q4 2020, filed 12 Feb 2021.